Open AccessMAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Author(s) -
Christine E. Ryan,
Matthew S. Davids,
Richard Hermann,
Mina Shahkarami,
Juliana Biondo,
Sarang Abhyankar,
Hasan Alhasani,
Jeff P. Sharman,
Anthony R. Mato,
Lindsey E. Roeker
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0456
Subject(s) - venetoclax , obinutuzumab , chronic lymphocytic leukemia , medicine , ighv@ , oncology , regimen , lymphoma , ibrutinib , leukemia , immunology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom